Cargando…
Circulating Tumor Cell Enumeration for Serial Monitoring of Treatment Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma
SIMPLE SUMMARY: Esophageal cancer is an aggressive disease with dismal survival. Circulating tumor cells (CTCs) may provide useful information for the unmet needs of early predictive and prognostic biomarkers for therapeutic responses and disease progression. Our novel longitudinal CTC findings demo...
Autores principales: | Ko, Josephine Mun Yee, Lam, Ka On, Kwong, Dora Lai Wan, Wong, Ian Yu-Hong, Chan, Fion Siu-Yin, Wong, Claudia Lai-Yin, Chan, Kwan Kit, Law, Tsz Ting, Chiu, Keith Wan Hang, Lam, Candy Chi Shan, Wong, Jean Chrysei, Fong, Henry Chun Hung, Choy, Faith Sin Fai, Lo, Andy, Law, Simon, Lung, Maria Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913330/ https://www.ncbi.nlm.nih.gov/pubmed/36765790 http://dx.doi.org/10.3390/cancers15030832 |
Ejemplares similares
-
Multigene Profiling of Circulating Tumor Cells in Esophageal Squamous Cell Carcinoma Identifies Prognostic Cancer Driver Genes Associated with Epithelial-Mesenchymal-Transition Progression and Chemoresistance
por: Tan, Zhen, et al.
Publicado: (2023) -
Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma
por: Ko, Josephine Mun Yee, et al.
Publicado: (2020) -
Histological Regression of Squamous Esophageal Carcinoma Assessed by Percentage of Residual Viable Cells after Neoadjuvant Chemoradiation is an Important Prognostic Factor
por: Tong, Daniel King Hung, et al.
Publicado: (2010) -
Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma
por: Ko, Josephine Mun-Yee, et al.
Publicado: (2022) -
Adjuvant Chemotherapy in Older Patients with Gastric Cancer: A Population-Based Cohort Study
por: Chan, Wing-Lok, et al.
Publicado: (2023)